Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus.
Hong ZhangXiaoxue ZhuQingmei LiJinfeng LouJixuan SunZhenwei ShenHong ChenXiaojiao LiMin WuCuiyun LiJingrui LiuChengjiao LiuYue HuJing WangGuiling ChenYanhua DingJunqi NiuPublished in: The Journal of pharmacy and pharmacology (2018)
This study shows that yimitasvir phosphate was well tolerated, and the PK profile supported daily dosing regimens. A 1-week (7-day) treatment course led to a quick and significant reduction in HCV RNA level in this cohort with HCV GT-1 infection.
Keyphrases
- hepatitis c virus
- clinical evaluation
- human immunodeficiency virus
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- physical activity
- prognostic factors
- open label
- randomized controlled trial
- patient reported outcomes
- placebo controlled
- smoking cessation
- double blind
- replacement therapy
- hiv infected